氧化酶和多药耐药性蛋白的遗传多态性与多克索鲁比诱导的心脏毒性有关
Leszek Wojnowski1, Bettina Kulle, Markus Schirmer
1Department of Pharmacology, University Mainz, D-55101 Mainz, Germany. Wojnowski@uni-mainz.de
Circulation
|December 7, 2005
概括
药物运输和新陈代谢中的遗传变异影响了人环素诱导的心脏毒性 (ACT) 风险. 识别这些药物基因组预测因素可以帮助个性化癌症治疗并减轻心脏损伤.
科学领域:
- 药物基因组学 药物基因组学
- 心脏病学 心脏病学
- 在瘤学瘤学.
背景情况:
- 抗环素化疗可以引起心脏毒性 (ACT),导致心律失常或心力衰竭.
- 目前,ACT的药物基因学预测因子尚未确定.
研究的目的:
- 研究基因变异作为抗环素诱导心脏毒性 (ACT) 的预测因素.
主要方法:
- 在82个相关基因中对1697名非霍奇金淋巴瘤患者进行基因定型单核酸多态 (SNP) 检测.
- 随访患者的中位数为>3年,以记录急性和慢性ACT发展.
- 分析了SNP和ACT发病率之间的关联,包括NAD(P) H氧化酶和多克索鲁素载体基因.
主要成果:
- 在NAD(P) H氧化酶子单元 (NCF4,CYBA,RAC2) 和多克索鲁素流量载体 (MRP1,MRP2) 中发现了ACT与多态性之间的显著关联.
- 像NCF4 (rs1883112) 和CYBA (rs4673) 这样的特定变异与分别慢性和急性ACT有关.
- 缺乏NAD(P) H氧化酶活性的小鼠对多克索鲁比辛表现出耐药性,支持该途径的作用.
结论:
- 参与多克索鲁比运输和自由基代谢的基因变异与ACT风险有关.
- 这些发现表明,药物基因组分析可能有助于预测和管理在接受 antracyclines 患者的 ACT .
相关概念视频
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
350
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
350
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
190
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
190
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Drug Toxicity: Risk factors
250
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
250
Drug toxicity: Idiosyncratic Reactions
232
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
232


